AGP Picks
View all

Piraeus Medical launches 35 Helix neurovascular guidewire in the US

Nov. 18, 2026
By AI, Created 22:28 UTC, Nov 18, 2026, AGP -

Piraeus Medical has launched the 35 Helix Neurovascular Guidewire in the United States after FDA clearance, adding a new 0.035-inch device to its neurointerventional portfolio. The company says the guidewire’s patent-pending construction reduces contact area versus competing wires, and early U.S. case use includes a reported TICI 3 stroke result.

Why it matters: - The 35 Helix Guidewire expands Piraeus Medical’s neurointerventional access portfolio with a new 0.035-inch option for physicians treating neurovascular and peripheral cases. - Piraeus Medical says the guidewire’s Helix construction reduces contact area by 58% versus competitive 0.035-inch wires, a design claim aimed at improving device performance in complex procedures. - The launch adds another tool alongside the 6F 70 NeuGlide™, 7F 87 NeuGlide+™ and 8F 93 NeuFlex™ Catheters.

What happened: - Piraeus Medical announced the U.S. launch of the 35 Helix Neurovascular Guidewire on Nov. 18, 2026, in Maple Grove, Minnesota, following FDA clearance. - The company said the first 35 Helix Guidewire cases have now been completed in the U.S. - The 35 Helix is built on Piraeus Medical’s patent-pending Helix construction.

The details: - The 35 Helix Guidewire is intended for general vascular use by a physician to introduce and position catheters or other interventional devices within the neuro and peripheral vasculatures. - The device is not intended for use in the coronary vasculature. - Indications, contraindications, warnings and instructions for use are included in the product labeling supplied with each device. - The product is for healthcare professionals only. - More information is available in the company’s announcement. - Piraeus Medical Customer Service can be reached at +1 507-782-0184.

Between the lines: - The launch message is centered on clinician feedback and product iteration, with CEO Jared Hutar saying the company builds solutions from physician input and first-principles design. - In a quoted case example, L. Luciano Ponce Mejia, MD, said the guidewire helped deliver a NeuGlide+ catheter and a 6F aspiration catheter through a 7F sheath to a basilar tip occlusion without exchanges. - In that case, Mejia reported TICI 3 reperfusion 9 minutes after puncture and 4 minutes of fluoroscopy. - The case quote positions the 35 Helix as a workflow simplifier in difficult neurovascular interventions, but it is still a single reported example.

What's next: - Piraeus Medical will likely use early U.S. case experience to support broader adoption of the 35 Helix Guidewire among neurointerventional physicians. - The company’s next challenge is proving that the launch claims translate into repeatable performance across more cases and centers.

The bottom line: - Piraeus Medical is betting that a patent-pending guidewire design and early clinical wins will help the 35 Helix stand out in the neurovascular access market.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

North America Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

North America Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.